Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient

被引:44
作者
Bunnik, Evelien M.
Quakkelaar, Esther D.
van Nuenen, Ad C.
Boeser-Nummink, Brigitte
Schuitemaker, Hanneke
机构
[1] Sanquin Res, Dept Clin Viroimmunol, NL-1066 CX Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1066 CX Amsterdam, Netherlands
[3] CINIMA, NL-1066 CX Amsterdam, Netherlands
关键词
D O I
10.1128/JVI.01983-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
CXCR4-using (X4) human immunodeficiency virus type 1 (HIV-1) variants evolve from CCR5-using (R5) variants relatively late in the natural course of infection in 50% of HIV-1 subtype B-infected individuals and subsequently coexist with R5 HIV-1 variants. This relatively late appearance of X4 HIV-1 variants is poorly understood. Here we tested the neutralization sensitivity for soluble CD4 (sCD4) and the broadly neutralizing antibodies IgG1b12, 2F5, 4E10, and 2G12 of multiple coexisting clonal R5 and (R5)X4 (combined term for monotropic X4 and dualtropic R5X4 viruses) HIV-1 variants that were obtained at two time points after the first appearance of X4 variants in five participants of the Amsterdam Cohort Studies on HIV-1 infection and AIDS. Recently emerged (R5)X4 viruses were significantly more sensitive to neutralization by the CD4-binding-site-directed agents sCD4 and IgG1b12 than their coexisting R5 viruses. This difference was less pronounced at the later time point. Early (R5)X4 variants from two out of four patients were also highly sensitive to neutralization by autologous serum (50% inhibition at serum dilutions of > 200). Late (R5)X4 viruses from these two patients were neutralized at lower serum dilutions, which suggested escape of X4 variants from Immoral immunity. Autologous neutralization of coexisting R5 and (R5)X4 variants was not observed in the other patients. In conclusion, the increased neutralization sensitivity of HIV-1 variants during the transition from CCR5 usage to CXCR4 usage may imply an inhibitory role for Immoral immunity in HIV-1 phenotype evolution in some patients, thus potentially contributing to the late emergence of X4 variants.
引用
收藏
页码:525 / 531
页数:7
相关论文
共 37 条
  • [11] EQUAL LEVELS OF GP120 RETENTION AND NEUTRALIZATION RESISTANCE OF PHENOTYPICALLY DISTINCT PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS UPON SOLUBLE CD4 TREATMENT
    GROENINK, M
    MOORE, JP
    BROERSEN, S
    SCHUITEMAKER, H
    [J]. JOURNAL OF VIROLOGY, 1995, 69 (01) : 523 - 527
  • [12] HARRIS ME, 1995, RNA, V1, P210
  • [13] No selection for CCR5 coreceptor usage during parenteral transmission of macrophagetropic syncytium-inducing human immunodeficiency virus type 1
    Koning, FA
    Schols, D
    Schuitemaker, H
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (18) : 8848 - 8853
  • [14] Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection
    Koot, M
    vantWout, AB
    Kootstra, NA
    deGoede, REY
    Tersmette, M
    Schuitemaker, H
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (02) : 349 - 354
  • [15] Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis
    Koot, M
    van Leeuwen, R
    de Goede, REY
    Keet, IPM
    Danner, S
    Schattenkerk, JKME
    Reiss, P
    Tersmette, M
    Lange, JMA
    Schuitemaker, H
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) : 254 - 258
  • [16] EVOLUTION OF THE V3 ENVELOPE DOMAIN IN PROVIRAL SEQUENCES AND ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 DURING TRANSITION OF THE VIRAL BIOLOGICAL PHENOTYPE
    KUIKEN, CL
    DEJONG, JJ
    BAAN, E
    KEULEN, W
    TERSMETTE, M
    GOUDSMIT, J
    [J]. JOURNAL OF VIROLOGY, 1992, 66 (07) : 4622 - 4627
  • [17] Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity
    LaCasse, RA
    Follis, KE
    Moudgil, T
    Trahey, M
    Binley, JM
    Planelles, V
    Zolla-Pazner, S
    Nunberg, JH
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (03) : 2491 - 2495
  • [18] Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1
    Li, Bing
    Decker, Julie M.
    Johnson, Roy W.
    Bibollet-Ruche, Frederic
    Wei, Xiping
    Mulenga, Joseph
    Allen, Susan
    Hunter, Eric
    Hahn, Beatrice H.
    Shaw, George M.
    Blackwell, Jerry L.
    Derdeyn, Cynthia A.
    [J]. JOURNAL OF VIROLOGY, 2006, 80 (11) : 5211 - 5218
  • [19] Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains
    Lusso, P
    Earl, PL
    Sironi, F
    Santoro, F
    Ripamonti, C
    Scarlatti, G
    Longhi, R
    Berger, EA
    Burastero, SE
    [J]. JOURNAL OF VIROLOGY, 2005, 79 (11) : 6957 - 6968
  • [20] Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage
    Montefiori, DC
    Collman, RG
    Fouts, TR
    Zhou, JY
    Bilska, M
    Hoxie, JA
    Moore, JP
    Bolognesi, DP
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (03) : 1886 - 1893